CDMO Symbiosis Expands Biologics Manufacturing CapacityCDMO Symbiosis Expands Biologics Manufacturing Capacity

December 17, 2019

5 Min Read
Powder Bulk Solids logo in a gray background | Powder Bulk Solids

Specialist sterile manufacturing and Contract Manufacturing Organization (CMO) Symbiosis Pharmaceutical Services, has expanded its sterile biologics manufacturing facility in Scotland, UK by 25%, the company announced in a release Tuesday. 

In the last 12 months Symbiosis has invested over £1.5m ($1.9 million) in the expansion of its Stirling site, doubling its current footprint with an additional 8000 sq ft of office space to house the firm’s administrative, management and operational teams while also facilitating the expansion of its existing manufacturing space and its supporting services infrastructure.

The new operational area also provides additional capacity for GMP-compliant manufacturing services for improved supply chain management including additional temperature controlled storage and the company’s first automated labelling and packaging equipment.

“This represents another exciting step for Symbiosis which allows the company to continue to leverage its expertise in small scale clinical and commercial sterile manufacturing to drive future growth. The additional space has allowed us to increase our headcount from 60 to 90 employees in line with both customer demand and our ongoing growth strategy,” said Symbiosis Chief Executive Officer Colin MacKay in a statement. “The investment in the new facility is driven by the significant organic growth of the company as a result of its continued success in the niche market of sterile manufacturing of advanced therapeutic medicinal products (ATMPs) such as viral vector and other biopharmaceuticals -  our customer base has grown by more than 25% in 2019 alone.”

The expanded facility, which was recently completed and is now fully operational, has been part-funded by a successful Innovate UK grant from the UK Government aimed directly at strengthening the UK’s viral vector biopharmaceutical drug development and manufacturing supply chain. The continued investment and demand for services is estimated to increase output by another 25-30% in 2020.

“The recent Innovate UK grant, combined with a successful FDA inspection, is further proof of Symbiosis’ continued profitable growth following its success in 2018 and throughout 2019. The strategic focus of Symbiosis for 2020 is on the continued organic growth of our core sterile GMP manufacturing services in our key target markets in the US and Europe,” said MacKay. ”Expanding the level of viral vector sterile manufacturing is central to that strategy, and we have a number of new and current client project initiatives which are further driving that expansion.”

As well as the growth of its specialist viral vector filling services, Symbiosis services the demand for sterile fill-finish of conventional small molecule drugs in both liquid and lyophilised formulations for clinical trials, and also has experience of supporting fast-track international commercial product registration.

This June, the company announced the completion of a viral vector supply chain collaboration with Cobra Biologics (Cobra), an international contract development and manufacturing organisation (CDMO) focused on viral vector drug substance production.

For more news headlines, articles, and equipment reviews, visit our Equipment Zones

More Powder & Bulk Solids articles:

Packaging Firm Fined $194K for Unsafe FIBC Stacking

Hostess Buys Cookie Manufacturer Voortman for $320M

GEAPS Announces Course Schedule for January 2020

Sign up for the Powder & Bulk Solids Weekly newsletter.

You May Also Like